Carl Zeiss Meditec (ETR:AFX) Shares Up 1.3% - Should You Buy?

Key Points

• Carl Zeiss Meditec AG shares rose 1.3% to €47.72 ($55.49), with trading volume increasing by 107% from its average session volume.
• The company has a market cap of $4.45 billion and a price-to-earnings ratio of 25.50, indicating strong market performance.
• Carl Zeiss Meditec specializes in medical technology, particularly in Ophthalmology and Microsurgery, offering solutions for chronic eye diseases.

Carl Zeiss Meditec AG (ETR:AFX - ) shot up 1.3% on Wednesday . The stock traded as high as €48.36 ($56.23) and last traded at €47.72 ($55.49). 195,822 shares changed hands during trading, an increase of 107% from the average session volume of 94,405 shares. The stock had previously closed at €47.10 ($54.77).

Carl Zeiss Meditec Trading Up 1.3%

The company has a debt-to-equity ratio of 7.41, a quick ratio of 2.47 and a current ratio of 2.13. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 25.50, a PEG ratio of 2.83 and a beta of 0.98. The business has a fifty day simple moving average of €43.82 and a 200-day simple moving average of €51.48.

Carl Zeiss Meditec Company Profile

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.